This article is for informational and educational purposes only and does not constitute medical advice. Pancreagen is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Pancreagen is a synthetic tetrapeptide composed of lysine, glutamic acid, aspartic acid, and tryptophan (Lys-Glu-Asp-Trp; single-letter: KEDW), developed by the research group of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the peptide bioregulator class — a series of short synthetic peptides proposed to modulate gene expression in a tissue-specific manner by interacting with DNA regulatory elements. Cell-based studies, conducted predominantly within the Khavinson laboratory, have examined Pancreagen’s proposed influence on pancreatic gene expression programs, including transcription factors associated with beta cell identity and insulin signaling pathways. Molecular docking analyses have additionally examined KEDW’s potential interactions with promoter sequences of pancreatic development genes. No peer-reviewed clinical trials evaluating Pancreagen in human subjects have been published; all available mechanistic and pharmacological evidence derives from cell-based assays, animal studies, and in silico analyses.
1. Background
1.1 Peptide Bioregulators — The Khavinson Class
The peptide bioregulator concept was developed from the 1970s onward by Vladimir Khavinson and colleagues at the Institute of Bioregulation and Gerontology in St. Petersburg, proposing that short peptides of two to four residues could regulate tissue-specific gene expression. Pancreagen is the pancreatic member of that series, and it enters an unusually crowded field: pancreatic and glycemic biology is among the most intensively studied areas in medicine, with well-characterized comparators against which any new mechanism is measured.
The class includes a range of named compounds, each proposed to target specific tissue types: Epitalon (Ala-Glu-Asp-Gly) for the pineal gland, Cardiogen (Ala-Glu-Asp-Arg) for cardiac tissue, Vilon (Lys-Glu) for immune regulation, Livagen (Lys-Glu-Asp-Ala) for hepatic tissue, and Pancreagen (Lys-Glu-Asp-Trp) for the pancreas, among others. The biological rationale for tissue specificity — why a short peptide would preferentially influence gene expression in one tissue over another following systemic administration — has not been mechanistically established through independent research [2].
1.2 The Pancreas and Metabolic Aging
The pancreas serves dual functions: an exocrine role in producing digestive enzymes for nutrient breakdown, and an endocrine role in which the islets of Langerhans — comprising alpha, beta, delta, and other specialized cell types — regulate blood glucose homeostasis through the secretion of insulin, glucagon, and somatostatin. Beta cells, which produce and secrete insulin, are of particular interest in metabolic aging research due to their vulnerability to oxidative stress, inflammatory signaling, and glucotoxicity.
Pancreatic beta cell function declines with age in parallel with increasing rates of type 2 diabetes in aging populations. The transcription factors governing beta cell identity and function — including Pdx1, Pax4, Nkx2.2, Nkx6.1, and Foxa2 — have been the focus of substantial research into pancreatic development, regeneration, and disease [3]. Pancreagen’s development within the Khavinson group was motivated by the hypothesis that a short peptide modeled on pancreatic tissue-derived sequences could support gene expression programs relevant to pancreatic cell function and metabolic homeostasis in aging.
1.3 Historical and Research Context
The Pancreagen literature is concentrated in cell-based gene-expression work from the Khavinson group, published predominantly in Russian-language journals, supported by molecular docking analyses of promoter interactions. What that record does not contain is functional metabolic data: the reported endpoints are transcription-factor and expression markers rather than measured insulin secretion or glucose handling. No independent laboratory has published a replication [1].
2. Molecular Structure
Pancreagen is a tetrapeptide with the sequence Lys-Glu-Asp-Trp, abbreviated in single-letter code as KEDW. At four residues it is among the shortest peptides in the research peptide class, alongside Epitalon (AEDG), Cardiogen (AEDR), and Livagen (KEDA).
| Property | Detail |
|---|---|
| Full name | L-Lysyl-L-glutamyl-L-aspartyl-L-tryptophan |
| Sequence (single-letter) | KEDW |
| Length | 4 amino acids (tetrapeptide) |
| Molecular formula | C₂₆H₃₆N₆O₉ |
| Molecular weight | ~577 Da |
| Net charge (physiological pH) | Mixed: one basic (Lys), two acidic (Glu, Asp), one aromatic neutral (Trp) |
| Post-translational modifications | None; fully synthetic |
| Water solubility | High |
| Class | Peptide bioregulator (Khavinson group) |
The tryptophan residue at the C-terminus distinguishes Pancreagen from other KED-containing bioregulators in the Khavinson series (such as Testagen and Vesugen). Tryptophan’s indole side chain is aromatic and participates in stacking interactions with DNA bases in the major groove, a feature of interest to the Khavinson group’s proposed DNA-binding mechanism. The lysine residue at position 1 provides a positively charged ε-amino group capable of electrostatic interaction with the negatively charged phosphate backbone of DNA [2].
3. Proposed Mechanisms
The mechanisms below have been proposed in cell-based, animal model, and computational studies. None has been confirmed in controlled human interventional research. All mechanistic claims originate predominantly from the Khavinson group.
4. Key Research Findings
| Research Area | Evidence Level | Best Available Evidence |
|---|---|---|
| Pancreatic gene expression (cell-based) | Limited Cell-based only |
Khavinson group; cell culture studies |
| DNA interaction / promoter binding | Limited In silico + cell-based |
Tarnovskaya et al. 2014 (Adv Gerontol) |
| Beta cell transcription factor modulation | Limited Cell-based only |
Khavinson group; single research center |
| Metabolic / insulin pathway context | Limited Cell-based only |
Limited published literature; no independent replication |
| Animal model (diabetic models) | Limited Khavinson group only |
Limited; predominantly from originating laboratory |
| Human clinical evidence | Limited None published |
No peer-reviewed trials identified |
4.1 Pancreatic Cell Gene Expression Studies
Cell-based studies from the Khavinson group have examined the effect of KEDW exposure on gene expression in pancreatic cell preparations, reporting associations with altered expression of genes related to cell identity, function, and aging [1]. These findings were interpreted as consistent with the general bioregulator hypothesis — that short peptides can shift gene expression programs in organ-specific target cells toward patterns associated with younger or healthier tissue states. The specific gene targets, effect magnitudes, and experimental conditions across these studies have not been fully characterized in peer-reviewed literature accessible through international databases.
Schematic representation of the proposed KEDW–DNA interaction as described in the Khavinson group’s molecular docking framework [2]. This diagram is conceptual and does not represent experimentally confirmed binding. No independent experimental validation of this interaction in living cells has been published.
4.2 DNA Interaction and Gene Regulatory Mechanism
Tarnovskaya et al. (2014) described the mechanistic framework by which short bioregulator peptides interact with DNA. Using molecular modeling and docking analyses, the group proposed that short peptides bind to specific nucleotide sequences in promoter regions of target genes, with charged residues forming electrostatic contacts with the DNA phosphate backbone and aromatic residues participating in base-stacking interactions within the major groove [2]. For KEDW, the tryptophan indole ring is proposed to contribute aromatic stacking with nucleobases, potentially enhancing binding affinity relative to non-aromatic short peptides in the class.
Different short peptide sequences were reported to show preferential in silico affinity for different DNA nucleotide motifs, providing the proposed theoretical basis for tissue-specific gene regulation by different named bioregulators. The applicability of these in silico binding affinities to transcriptional regulation in living cells — where peptides must compete with histones, transcription factors, and other DNA-binding proteins at far higher effective concentrations — has not been independently verified by structural or biochemical methods such as ChIP, EMSA, or DNase I footprinting.
4.3 Beta Cell Transcription Factor Context
Pancreatic beta cell identity is maintained by a network of transcription factors that are well-characterized in the independent literature. Pdx1 (pancreatic and duodenal homeobox 1) is essential for both pancreatic development and mature beta cell function, regulating the expression of insulin, somatostatin, and glucose transporter genes [3]. Pax4 and Nkx2.2 cooperate with Pdx1 to establish and maintain the beta cell transcriptional program. Loss of these factors in animal models results in impaired insulin secretion and diabetes-like phenotypes.
The Khavinson group has proposed that Pancreagen exposure is associated with gene expression changes consistent with support of these beta cell identity programs in aging cell models. The mechanism — whether KEDW directly modulates Pdx1 or related promoters, or whether any observed cell-culture effects reflect indirect or non-specific outcomes at the concentrations studied — has not been resolved in the published literature.
5. Evidence Status
| Evidence Type | Current Status |
|---|---|
| Cell-based pancreatic gene-expression studies | Published (Khavinson group; predominantly Russian-language journals) |
| Beta-cell identity transcription factors (including PDX1) | Proposed influence reported at marker level in cell preparations |
| In silico docking to gene promoter sequences | Published; predicted binding geometry, not experimentally confirmed |
| Insulin secretion measured functionally | Not demonstrated; reported endpoints are expression markers, not secreted insulin |
| Animal studies in metabolic or diabetic models | Limited; predominantly from the originating laboratory |
| Comparison against established incretin or insulin pharmacology | Not performed in any published study |
| Human glycemic outcomes, safety or pharmacokinetics | No published trial at any phase |
What We Still Don’t Know
- Whether the proposed DNA-binding mechanism operates in living pancreatic cells: The in silico docking analyses propose a specific interaction between KEDW and gene promoter sequences, but whether this peptide at pharmacologically achievable intracellular concentrations actually binds to chromatin-associated DNA in intact pancreatic cells has not been demonstrated by independent investigators using established biochemical methods.
- Whether tissue specificity exists and how it would operate: The claim that Pancreagen preferentially targets pancreatic tissue is central to its classification as a bioregulator, but no published pharmacokinetic or pharmacodynamic study has demonstrated tissue-preferential distribution of KEDW to pancreatic tissue relative to liver, kidney, or other tissues following systemic administration.
- The effect on beta cell function in controlled models: While the Khavinson group has reported associations with beta cell gene expression markers, dose-response relationships, effect duration, and reproducibility across independent cell lines or animal models have not been characterized in the peer-reviewed literature accessible internationally.
- Human safety and pharmacokinetics: No published phase 1 trial characterizes the safety, tolerability, half-life, or target tissue distribution of Pancreagen in humans. As a tetrapeptide, it would be expected to undergo hydrolysis by plasma and tissue peptidases, but pharmacokinetic data in any species other than rodent are absent from the accessible literature.
- Whether Trp at position 4 confers meaningful functional differences from KED-containing bioregulators: Testagen (KED) and Vesugen (KED) share the first three residues with Pancreagen. Whether the Trp extension meaningfully changes DNA binding specificity, cellular uptake, or biological activity — beyond what is predicted by in silico docking — has not been experimentally determined.
- Effective dose and route of administration in any in vivo context: Dose-response data in animal models and the pharmacologically active concentration range in living tissue are not characterized in the independent literature.
6. Limitations of Current Research
References
- Khavinson VKh, Linkova NS, Kvetnoy IM, Kvetnaia TV, Polyakova VO, Korf HW. “Short bioregulatory peptides modulate gene expression in epithelial and endocrine tissues during aging.” Advances in Gerontology. 2012;25(2):215–221.
- Tarnovskaya SI, Khavinson VKh, Linkova NS, Pronyaeva VE, Kolchina NV, Tendler SM. “Mechanism of Short Peptides Interaction with DNA.” Advances in Gerontology. 2014;27(4):706–714.
- Habener JF, Kemp DM, Thomas MK. “Minireview: transcriptional regulation in pancreatic development.” Endocrinology. 2005;146(3):1025–1034. doi:10.1210/en.2004-1576
- Khavinson VKh, Tarnovskaya SI, Linkova NS. “Epigenetic aspects of the short peptides bioregulators action.” Epigenetics. 2013;8(8):1–10.